

Jubilant Therapeutics Inc.
Balance Sheet as at 31 March 2023

		USD	USD
	Notes	As at 31 March 2023	As at 31 March 2022
ASSETS			
Non-current assets			
Property, plant and equipment	3	7,947	17,454
Right of use assets	4	50,634	99,257
Financial assets			
i. Non-current investments	5	30,832,562	24,982,562
ii. Other financial assets	6	13,200	13,200
Other non-current assets	7	107,122	124,827
Total non-current assets		31,011,464	25,237,300
Current assets			
Financial assets			
i. Cash and cash equivalents	8	2,108,006	1,697,026
ii. Short term loan and advances	9	50,826	95,106
iii. Other financial assets	10	927,718	775,962
Other current assets	11	151,917	140,160
Total current assets		3,238,467	2,708,254
Total assets		34,249,931	27,945,554
EQUITY AND LIABILITIES			
Equity			
Equity share capital	12	562	564
Other equity		(25,764,673)	(11,545,568)
Total equity		(25,764,111)	(11,545,004)
LIABILITIES			
Non- current liabilities			
Financial liabilities	13	56,065	106,520
Stock settled debt instrument	14	58,143,057	38,021,521
Total non-current liabilities		58,199,123	38,128,041
Current liabilities			
Financial liabilities			
i. Trade payables	15	1,354,254	940,922
ii. Other financial liabilities	16	459,565	420,495
Current tax liabilities(Net)		1,100	1,100
Total current liabilities		1,814,919	1,362,517
Total liabilities		60,014,042	39,490,558
Total equity and liabilities		34,249,931	27,945,554

Jubilant Therapeutics Inc.
Statement of Profit and Loss for the period ended 31 March 2023

		USD	USD
	Notes	For the year ended 31 March 2023	For the year ended 31 March 2022
Revenue from operations		-	-
Other income	17	29,861	1,043
Total income		29,861	1,043
Expenses			
Employee benefits expenses	18	1,599,522	1,469,623
Finance costs	19	9,193,145	649,052
Depreciation and amortization expense	20	58,349	59,290
Other expenses	21	3,386,839	3,456,400
Total expenses		14,237,854	5,634,365
Loss before tax		(14,207,993)	(5,633,321)
Tax expense			
- Current tax		1,100	1,100
- Deferred tax		-	-
Total tax expense		1,100	1,100
Loss for the year		(14,209,093)	(5,634,421)
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Exchange differences on translation of foreign operations		-	-
Other comprehensive loss for the year, net of tax		-	-
Total comprehensive loss for the year		(14,209,093)	(5,634,421)

Jubilant Therapeutics Inc
Statement of changes in equity for the year ended 31 March 2023

A) Equity Share Capital

	USD
Balance as at 1 April 2021	531
Additions during the year	33
Balance as at 31 March 2022	564
Additions during the year	(2)
Balance as at 31 March 2023	562

B) Other equity

	USD			
	Reserves and Surplus			
	Share based payment	Securities Premium	Retained earnings	Total
Balances as at 1 April 2021	109,532	8,223,668	(6,416,694)	1,916,506
Addition during the year	-	475,607	-	475,607
Loss for the year	-	-	(5,634,421)	(5,634,421)
Adjustment during the year	-	-	(8,252,424)	(8,252,424)
Share based payment reserve	(50,836)	-	-	(50,836)
Total comprehensive loss for the year	(50,836)	475,607	(13,886,845)	(13,462,074)
Balances as at 31 March 2022	58,696	8,699,275	(20,303,539)	(11,545,568)

	USD			
	Reserves and Surplus			
	Share based payment	Securities Premium	Retained earnings	Total
Balances as at 1 April 2022	58,696	8,699,275	(20,303,539)	(11,545,568)
Addition during the year	-	(23,693)	-	(23,693)
Loss for the year	-	-	(14,209,093)	(14,209,093)
Adjustment during the year	-	-	10,090	10,090
Share based payment reserve	3,591	-	-	3,591
Total comprehensive loss for the year	3,591	(23,693)	(14,199,003)	(14,219,105)
Balances as at 31 March 2023	62,287	8,675,582	(34,502,542)	(25,764,673)

Jubilant Therapeutics Inc.
Statement of Cash Flows for the period ended 31 March 2023

	USD	USD
	For the year ended 31 March 2023	For the year ended 31 March 2022
A. Cash flow from operating activities		
Loss before tax	(14,207,993)	(5,633,321)
Adjustments :		
Depreciation	58,349	59,290
Share based expense	21,055	83,993
Finance costs	1,012,060	649,052
Interest income	(29,861)	(1,043)
Net loss arising on financial liability measured at fair value through profit or loss	8,181,084	-
Operating cash flow before working capital changes	(4,965,306)	(4,842,030)
Increase in other financial assets	(107,475)	3,009,526
Decrease in other current assets	(25,121)	(296,739)
(Decrease)/ increase in trade payables and other liabilities	385,251	(121,176)
Cash used in operations	(4,712,651)	(2,250,418)
Income tax paid (net of refund)	(1,100)	(1,100)
Net cash used in operating activities	(4,713,751)	(2,251,518)
B. Cash flow from investing activities		
Purchase of fixed assets	(219)	(3,667)
Investment in Subsidiaries	(5,850,000)	(12,300,000)
Net cash used in investing activities	(5,850,219)	(12,303,667)
C. Cash flow from financing activities		
Proceeds from long term borrowings	11,000,000	21,600,000
Repayment of borrowings	-	(6,600,000)
Interest received	29,861	1,043
Finance costs paid	(4,457)	(199,592)
Repayments of finance lease obligations	(50,455)	(46,815)
Net cash generated from financing activities	10,974,949	14,754,634
Net increase/(decrease) in cash and cash equivalents (A+B+C)	410,980	199,449
Add: cash and cash equivalents at the beginning of year	1,697,026	1,497,578
Cash and cash equivalents at the end of the year	2,108,006	1,697,026

Jubilant Therapeutics Inc.**Notes to the financial statements for the year ended 31 March 2023**

Note 1: Corporate information

Jubilant Therapeutics Inc. ("the Company") was incorporated in United States of America under the local laws of Delaware on 19 February 2019. The Company is a fully owned subsidiary of Jubilant Therapeutics India Limited., company incorporated in India ("the holding company") whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India. The company will focus on the development of novel drugs for the treatment of cancer in the area of Oncology and Auto-Immune disorders.

Note 2. Significant accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation**(i) Statement of compliance**

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Jubilant Therapeutics Inc.**Notes to the financial statements for the year ended 31 March 2023****Note 3: Property, Plant and equipment**

Description	USD	
	Office Equipment	Total
Gross carrying value as at 1 April 2022	36,020	36,020
Additions during the year	219	219
Gross carrying value as at 31 March 2023	36,239	36,239
Accumulated depreciation as at 1 April 2022	18,566	18,566
Depreciation charge for the year	9,726	9,726
Accumulated depreciation as at 31 March 2023	28,292	28,292
Net carrying value as at 31 March 2023	7,947	7,947

Jubilant Therapeutics Inc.
Notes to the financial statements for the year ended 31 March 2023

Note 4. Leases

	USD	USD
	For the year ended March 31, 2023	For the year ended March 31, 2022
Lease cost	198,527	198,527
Total lease cost	198,527	198,527
	As at	As at
	March 31, 2023	March 31, 2022
Leases:		
Lease ROU assets	50,634	99,257
Long-term portion of lease liabilities	1,773	56,069
Current installment of lease liabilities	54,293	50,451
Total lease liabilities	56,065	106,520
Total lease liabilities	56,065	106,520
	As at	As at
	March 31, 2023	March 31, 2022
Supplemental cash flow information:		
Cash paid for amounts included in the measurement of lease liabilities :		
Financing cash flow from leases	54,912	53,856
Weighted average remaining lease term:		
Lease	1.08 years	2.08 years
Weighted-average discount rate:		
Leases	5.50%	5.50%
	Leases	Leases
Years ending March 31,		
2023	-	54,912
2024	55,968	55,968
2025	2,332	2330
Thereafter	-	-
Total undiscounted lease payments	58,300	113,210
Less: imputed interest	2,231	6,690
Total lease liabilities	56,069	106,520

Jubilant Therapeutics Inc.
Notes to the financial statements for the year ended 31 March 2023

Note 5: Non-current investments

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Investment in equity shares (at cost)		
Unquoted equity shares (fully paid up)		
Subsidiary company		
Investment in subsidiaries		
Investment in Jubilant Epicore LLC	11,883,575	9,033,575
Investment in Jubilant Epipad LLC	6,801,230	6,001,230
Investment in Jubilant Episcribe LLC	5,306,440	4,106,440
Investment in Jubilant Prodel LLC	6,841,317	5,841,317
Total Non-current investment	30,832,562	24,982,562

Note 6: Other Financial Assets

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Securirty deposits	13,200	13,200
Total other non-current assets	13,200	13,200

Note 7: Other non-current assets

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Other long-term receivables	107,122	124,827
Total other non-current assets	107,122	124,827

Note 8: Cash and cash equivalents

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Balances with banks		
- in current accounts	2,108,006	1,697,026
Total cash and cash equivalents	2,108,006	1,697,026

Note 9: Short term loans and advances

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Staff advance against salary	50,826	95,106
Total Short term loans and advances	50,826	95,106

Note 10: Other financial assets

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Account receivables from related parties	927,718	775,962
Interest receivable	0	-
Total other financial assets	927,718	775,962

Jubilant Therapeutics Inc.
Notes to the financial statements for the year ended 31 March 2023

Note 11: Other current assets

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Prepaid expenses	90,480	14,660
Advance general	19,076	26,261
Other Current Assets	42,362	99,239
Total other current assets	151,917	140,160

Note 12: Equity share capital

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Issued, subscribed and paid up		
Equity Shares	562	564

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the Company:

	As at		As at	
	31 March 2023		31 March 2022	
	No of shares	% holding in the class	No of shares	% holding in the class
Name of the Shareholder				
Jubilant Therapeutics India Limited	105,200	94%	105,200	93%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	As at		As at	
	31 March 2023		31 March 2022	
	No of shares	USD	No of shares	USD
Numbers of shares at the beginning of the year	112,751	564	106,282	531
Add: Shares issued/(cancelled) during the year	(350)	(2)	6,469	33
Number of shares at the end of the year	112,401	562	112,751	564

	As at		As at	
	31 March 2023		31 March 2022	
	No of shares	No of shares	No of shares	No of shares
Numbers of shares at the beginning of the year		112,751		106,282
Add: Shares issued/(cancelled) during the year		(350)		6,469
Number of shares at the end of the year		112,401		112,751

5) Equity shares held by holding company/ultimate holding company is set out below:

	As at		As at	
	31 March 2023		31 March 2022	
	No of shares	% holding in the class	No of shares	% holding in the class
Jubilant Therapeutics India Limited	105,200	94%	105,200	93%

Jubilant Therapeutics Inc.
Notes to the financial statements for the period ended 31 March 2023

Note 13: Borrowings

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Non-Current		
Finance lease obligations	56,065	106,520
Total trade payables	56,065	106,520

Note 14: Stock settled debt instruments

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
*Stock settled debt instruments (Convertible Promissory Notes)	52,116,542	38,021,521
Optionally Convertible Debenture-JTI	6,026,516	-
Total Stock settled debt instruments	58,143,057	38,021,521

Note 15: Trade payables

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Trade payables	122,714	191,555
Due to related parties	1,231,540	749,367
Total trade payables	1,354,254	940,922

Note 16: Other financial liabilities

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Current		
Employee benefit payable	392,414	420,495
Accrued interest	67,150	-
Total other financial liability	459,565	420,495

Note 17: Other Income

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Interest Income	29861	1043
Total Interest Income	29,861	1,043

Note 18: Employee benefits expenses

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Salaries, wages, bonus, gratuity and allowances	1,351,276	1,238,823
Staff welfare expenses	9,875	1,128
Insurance mediclaim	217,317	145,678
Stock Based Compensation Expense	21,055	83,993
Total employee benefits expenses	1,599,522	1,469,623

Jubilant Therapeutics Inc.
Notes to the financial statements for the period ended 31 March 2023

Note 19: Finance costs

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Interest expense	1,007,603	642,011
Interest cost-right of use lease	4,457	7,041
Debt Initiation Cost-Dic Amortization	8,181,084	-
Total Finance costs	9,193,145	649,052

Note 20: Depreciation and amortization expense

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Depreciation of property, plant and equipment	9,726	10,666
Depreciation - Right of use assets	48,623	48,624
Total depreciation and amortization expense	58,349	59,290

Note 21: Other expenses

	USD	USD
	As at	As at
	31 March 2023	31 March 2022
Legal and professional fees	719,554	814,620
Job work/ Processing charges	1,162,796	1,010,827
Business/Sales Promotion	-	56,203
Chemicals consumed	332,498	338,005
Consultancy expenses	777,448	1,066,026
Recruitment and development expense	146	14,364
Meeting & conference expenses	86,902	27,198
License fees	-	23,724
Bank charges	28,512	9,823
Office maintenance	10,512	2,149
Rent	-	6,885
Rates & taxes	22	2,819
Printing and stationery	4,602	570
Subscription	125,152	32,893
Training expenses	12,314	-
Conveyance expenses	-	7,506
Travel and conveyance	114,472	40,413
Postage and telegram	11,465	434
Patent related expenses	(79)	1,942
Foreign exch loss-imports	523	-
Total other expenses	3,386,839	3,456,400